Introduction
Two patients can have infections caused by the same bacterial species and still need different antibiotics. A bacterial isolate is a population grown from a sample and selected for testing. One patient’s isolate may be susceptible to an antibiotic that has little effect on the other’s. Identifying the organism is therefore only part of the laboratory’s task: clinicians also need evidence about which treatments are likely to work.
Antibiotic susceptibility testing (AST) provides that evidence by examining bacterial responses under defined laboratory conditions. The need is substantial. In its 2025 global surveillance report, the World Health Organization (WHO) estimated that about one in six laboratory-confirmed bacterial infections covered in 2023 were resistant to antibiotic treatment. The estimate concerns the infection types and pathogens included in that assessment, rather than every infection occurring worldwide.
The report drew on more than 23 million bacteriologically confirmed infection episodes reported between 2016 and 2023, with 104 countries contributing data for 2023. Reliable testing makes such surveillance possible, but its immediate value is personal: an AST report can help a clinical team adjust treatment for the patient in front of them. The result must still be considered alongside the infection site, achievable drug exposure, patient response, and treatment safety.
This article explains the principles, main methods, and interpretation of AST for students and interested science readers. It focuses on routine testing of bacteria that grow aerobically. Anaerobes, mycobacteria, and fungi require their own applicable methods and interpretive guidance.
Figure 1. Illustrative overview of disk diffusion, broth microdilution to measure the minimum inhibitory concentration (MIC), and molecular detection of resistance markers. This is a conceptual illustration, not experimental data. Schematic, not to scale.
What Does an AST Result Mean?
Most routine AST methods measure bacterial growth in the presence of an antibiotic. These are called phenotypic tests because they measure an observable response. Depending on the method, the lab can report a measurement, such as an MIC or an inhibition-zone diameter, and use it to assign a category such as susceptible or resistant.
What the Test Measures
Minimum inhibitory concentration (MIC). The MIC is the lowest antibiotic concentration tested at which bacterial growth meets the method’s inhibition criterion. Many methods use the absence of visible growth as that criterion. MICs are commonly reported in mg/L or µg/mL, which are numerically equivalent.
Worked MIC example. Imagine that bacteria grow at 1 and 2 mg/L but show no visible growth at 4 and 8 mg/L. If the controls are valid and the test uses absence of visible growth as its endpoint, the MIC is 4 mg/L. That is the lowest tested concentration with no visible growth.
Quick check. Can the lab classify the isolate as susceptible to 4 mg/L alone? To assign a category, the lab needs to know which bacterium and antibiotic were tested and use the breakpoint for the applicable method.
Inhibition-zone diameter. In a disk diffusion test, the lab measures the width, in millimeters, of the area of inhibited growth around a disk. Interpreting that diameter requires the breakpoint for the organism, antibiotic, disk content, and method. Zone sizes for different antibiotics must each be interpreted using their own criteria.
Minimum bactericidal concentration (MBC). The MIC measures growth inhibition. The MBC measures killing. It is the lowest antibiotic concentration that achieves a defined reduction in viable bacteria, conventionally at least 99.9% relative to the starting inoculum. Clinical susceptibility categories are generally based on MICs or zone measurements. Reporting an MBC requires stating the procedure and the endpoint used.
Clinical Breakpoints: CLSI and EUCAST
A clinical breakpoint is a cutoff that helps the lab turn an MIC or an inhibition-zone diameter into a reporting category. Breakpoints draw on evidence about bacterial responses, clinical outcomes, and drug exposure, including how much active drug reaches the site of infection and for how long. The Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) publish widely used systems. Laboratories must pair the appropriate method with its applicable interpretive system and current organism–drug criteria.
The letter I is particularly easy to misread. In CLSI it means Intermediate; in EUCAST it means Susceptible, increased exposure. Table 1 separates the meanings. CLSI also uses susceptible-dose-dependent (SDD) for selected organism–drug combinations. These categories should never be translated merely by matching their letters.
| Category | CLSI | EUCAST |
|---|---|---|
| S | Susceptible at the recommended exposure for the relevant infection. | Susceptible with the standard dosing regimen specified by the breakpoint system. |
| I | Intermediate: response can be less certain. Drug concentration at particular sites, increased exposure, and a technical buffer can be relevant. | Susceptible, increased exposure: treatment can succeed when the specified higher exposure is achieved. |
| SDD | A separate category requiring the specified exposure regimen for selected organism–drug pairs. | SDD is not a separate EUCAST category; use EUCAST’s definitions and tables. |
| R | Resistance according to the relevant criteria; usual achievable concentrations are inadequate, and/or resistance evidence and clinical data indicate unreliable efficacy. | Treatment is unlikely to succeed even with increased exposure. |
EUCAST considers both S and I to be susceptible categories. In surveillance, I must therefore not be grouped with R as “resistant” or "non-susceptible". As of 18 November 2026, EUCAST’s clinical tables are version 16.1, valid from 24 June 2026, and CLSI’s annual tables are M100, 36th edition. Laboratories also need the associated method documents, quality-control tables, footnotes, and correction notices. Breakpoints can change as the evidence changes.
A laboratory result does not guarantee clinical success. The treating team must consider whether the antimicrobial reaches the infection site at an effective exposure, whether the patient can tolerate the treatment, and whether the organism and infection context are appropriately represented by the test result.
Figure 2. Schematic overview of routine AST. The workflow begins with a cultured isolate. Molecular tests can add evidence about selected resistance markers. Validated direct rapid methods can follow a different workflow.
Five steps in routine AST
- Identify the bacterium. Establish which organism the result will describe.
- Standardize the preparation. Prepare the isolate under the conditions defined for the test.
- Measure the response. Depending on the method, record a result such as an MIC or an inhibition-zone diameter.
- Interpret the measurement. Use the breakpoint for the bacterium, antibiotic, and test method to assign a category.
- Report and review. Confirm that quality controls passed, then report the result for the care team to consider alongside the patient’s clinical information.
Historical Development of Antibiotic Susceptibility Testing
Early antimicrobial susceptibility experiments used methods such as broth dilution and agar-based assays. Results could vary between laboratories because the media, bacterial inoculum, incubation conditions, and interpretation procedures were not always standardized. As antimicrobial treatment became more widely used, reproducible laboratory methods became increasingly important.
The widely used Kirby–Bauer approach became an important foundation for standardized disk diffusion. EUCAST later developed a disk-diffusion method calibrated to its clinical MIC breakpoints, described in a 2014 methods paper. This illustrates why a familiar technique still needs a defined medium, inoculum, reading procedure, and interpretive system: the measurement and its meaning must be calibrated together.
Later developments expanded AST beyond manual culture-based procedures. Broth microdilution, gradient diffusion, automated instruments, and molecular assays provided additional ways to estimate antimicrobial activity or detect resistance-associated genetic markers. These approaches answer related but different questions: phenotypic methods assess bacterial growth in the presence of an antimicrobial agent, whereas molecular methods detect selected genetic determinants associated with resistance.
Main Laboratory Methods
Standardization of Media and Inoculum
AST results can change with the culture medium, inoculum density, incubation conditions, and antimicrobial stability. The inoculum is the bacterial material introduced into the test. Mueller–Hinton agar is widely used for disk diffusion of non-fastidious bacteria, while cation-adjusted Mueller–Hinton broth is commonly used for dilution testing. Fastidious organisms, which have additional growth requirements, need the supplemented media specified by the chosen standard. Some organism–drug combinations also require modified conditions.
A 0.5 McFarland standard is a turbidity reference commonly used when preparing a bacterial suspension. Its approximate relationship to 1.5 × 108 colony-forming units per milliliter (CFU/mL) varies with the organism and preparation. A colony-forming unit represents viable material capable of producing a colony; it is not necessarily one cell. The suspension is then adjusted for the selected method. For example, routine broth microdilution generally targets about 5 × 105 CFU/mL in the final well, not an undiluted 0.5 McFarland suspension.
The composition of the medium also matters. Inappropriate concentrations of divalent cations can affect the activity of certain antimicrobial agents, such as aminoglycosides against Pseudomonas aeruginosa and daptomycin, which requires the calcium concentration specified by the method. Excess thymidine or thymine in the medium can interfere with the activity of trimethoprim and sulfonamides and may produce misleading results. For this reason, laboratories use media that meet the relevant quality specifications and follow the method-specific requirements.
Kirby–Bauer Disk Diffusion
In the disk diffusion method, a standardized bacterial suspension is spread over the surface of an appropriate agar plate to produce a uniform lawn of growth. Paper disks containing defined amounts of antimicrobial agents are placed on the agar. During incubation, the antimicrobial diffuses into the medium and forms a concentration gradient. If the organism is inhibited, a zone of reduced growth appears around the disk.
The diameter of each inhibition zone is measured and compared with the relevant breakpoint table. Disk diffusion is widely used because it is relatively inexpensive and does not require specialized automated equipment. However, it generally provides an interpretive category rather than a numerical MIC. Accurate results depend on standardized media, inoculum preparation, disk content, incubation conditions, quality control, and the use of current organism-specific criteria.
Broth Microdilution and Macrodilution
Broth dilution methods determine the MIC by exposing a standardized bacterial inoculum to a series of antimicrobial concentrations in liquid medium. Microdilution uses small-volume wells; macrodilution uses larger tubes. Concentrations commonly follow a twofold series, with each step double the preceding concentration. After the specified incubation, the MIC is read at the defined growth endpoint. Complete visible inhibition is used for many agents, but some require a modified endpoint, such as a specified reduction relative to the growth control. Agent-specific reading instructions therefore matter.
Broth microdilution is a reference method for MIC determination for many rapidly growing aerobic bacteria. EUCAST’s freely available broth-microdilution recommendations explain the reference approach and its relationship to ISO methodology. Quantitative results are useful, but preparation, growth controls, purity checks, and endpoint reading must be reliable. A drug-free growth control confirms that the organism can grow in the test conditions; an uninoculated control helps detect contamination. The numerical MIC does not independently determine a patient’s dose.
Agar Dilution
In agar dilution, defined concentrations of an antimicrobial agent are incorporated into separate agar plates. A standardized inoculum of each test organism is then applied to the surface of the appropriate plate, often using a multipoint inoculator. After incubation under specified conditions, growth is assessed at each antimicrobial concentration, and the MIC is determined from the lowest concentration that prevents the defined growth endpoint.
Agar dilution can test multiple isolates against defined antimicrobial concentrations and is useful in reference and research work. Preparing separate plates is labor-intensive, and its suitability depends on the organism, agent, and specified reference method. A need for enriched growth conditions does not by itself establish that agar dilution is preferable; laboratories must follow the applicable organism-specific guidance.
Gradient Diffusion Strips
Gradient diffusion tests use a strip carrying a predefined antimicrobial concentration gradient. After exposure and incubation on an inoculated agar surface, the MIC is estimated where the inhibition ellipse crosses the printed scale. The scale can include values between the concentrations used in twofold dilution tests. Reading, rounding, and interpretation must follow the product instructions and the applicable standard, rather than a universal rounding rule.
Gradient diffusion combines a relatively simple agar-based procedure with an MIC estimate. It can be useful when a quantitative result is needed for selected organism–drug combinations. However, strips are generally more expensive per test than standard disks, and endpoint reading can be difficult when growth is hazy, trailing, or otherwise atypical. Results should be interpreted according to the manufacturer’s instructions and relevant standards, and may require confirmation when clinically important discrepancies occur.
Automated AST Systems
Automated AST systems, including VITEK 2, BD Phoenix, and MicroScan WalkAway, are used in many clinical microbiology laboratories. Depending on the platform, these systems use cards or panels containing selected antimicrobial concentrations and monitor bacterial growth or related signals over time. Instrument software analyzes the results and generates MIC estimates or susceptibility categories according to the system’s validated algorithms and interpretive criteria.
Automation can increase testing throughput, reduce some manual steps, and support integration with laboratory information systems. Nevertheless, automated systems have limitations, including instrument and consumable costs, restricted antimicrobial panels, and the possibility of uncertain or discrepant results for particular organism–drug combinations or resistance mechanisms. A practical limitation is that the interpretive criteria loaded in a system may lag behind current CLSI or EUCAST breakpoints, so laboratories should verify which breakpoint version is in use. Commercial systems also require verification in the user’s own laboratory before clinical use, followed by ongoing quality assurance. Laboratories should follow manufacturer instructions, maintain quality control, and use confirmatory methods when indicated by the relevant standard or clinical context.
Molecular Detection of Resistance Genes
Molecular methods detect genetic markers associated with antimicrobial resistance. Techniques include polymerase chain reaction (PCR), multiplex PCR, DNA microarrays, and targeted sequencing. Examples include detection of mecA, which is associated with methicillin resistance in staphylococci, and selected bla genes that encode beta-lactamases. Carbapenemase gene targets include blaKPC, blaNDM, blaOXA-48-like, and blaVIM. Other targets include vanA and vanB in enterococci. Depending on the assay, testing may be performed on a positive blood culture, a bacterial isolate, or another validated specimen type.
Molecular assays can rapidly identify the resistance determinants included in their design. A positive result may guide particular reporting or treatment decisions under validated rules, but it does not usually provide a measured MIC or a complete susceptibility profile. A negative targeted panel also does not exclude resistance: the organism may carry an untested gene or mutation, or use another mechanism. Gene expression and the organism–drug context matter. Conventional PCR with endpoint detection, real-time PCR, and sequencing are different analytical routes; a gel and sequencing are not obligatory steps after every PCR assay. Table 2 compares the principal approaches.
| Method | Output | Main advantages | Main limitations |
|---|---|---|---|
| Disk diffusion | Zone diameter, interpreted as a category | Low cost; no specialized equipment | No MIC; depends on standardized media, inoculum, and disk content |
| Broth microdilution | MIC | Quantitative; reference approach for many organisms | Careful preparation; trained personnel |
| Agar dilution | MIC | Many isolates per plate; reference method for some agents | Labor-intensive plate preparation |
| Gradient strips | MIC estimate | MIC for selected organism–drug pairs with a simple procedure | Higher cost per test; hazy endpoints are hard to read |
| Automated systems | MIC estimate or category | High throughput; laboratory information system integration | Instrument cost; restricted panels; algorithm-dependent results |
| Molecular detection | Covered resistance marker detected or not detected | Rapid; some assays work directly on positive blood cultures | Only covered targets; a negative panel does not rule out all resistance or provide a complete phenotype |
Rapid AST: Accelerated Diagnostic Approaches
Many conventional culture-based workflows require overnight incubation once a suitable isolate is available. The exact interval depends on the organism, method, instrument, and reporting workflow. Total specimen-to-report time also includes any transport, primary culture, identification, and confirmatory work.
Rapid approaches shorten selected parts of that pathway. Examples include growth-based testing directly from validated positive blood cultures, early-response imaging, microfluidic methods, and rapid detection of resistance markers. EUCAST’s rapid disk-diffusion method, RAST, uses dedicated organism-, drug-, and reading-time-specific criteria. Depending on the validated combination, readings are made at 4, 6, 8, or 16–20 hours. Standard overnight disk-diffusion breakpoints must not be substituted for RAST breakpoints, and zones in an area of technical uncertainty require the actions specified by the method.
Rapid molecular tests can identify selected resistance determinants, whereas rapid phenotypic methods attempt to measure bacterial response to antimicrobial exposure. These approaches are complementary, not interchangeable. Laboratories must validate each method for its intended use and understand its limitations, including the organisms and resistance mechanisms it can detect. Conventional standardized methods may still be needed to resolve uncertain results or provide a complete susceptibility profile.
Quality Control and Method Standardization
Reliable AST results depend on quality control (QC) throughout the testing process. Factors such as agar depth, medium composition and pH, cation concentrations, inoculum density, antimicrobial disk potency, incubation conditions, and endpoint reading can influence zone diameters or MIC values. Standardized procedures help laboratories reduce technical variation and identify problems before patient results are reported.
Quality-control strains are reference organisms with expected MIC or zone ranges. EUCAST’s 2026 tables include Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213 among the routine controls for specified tests. These examples are not interchangeable universal controls, and other systems may specify different strains or ranges. The correct strain, medium, drug, method, and current acceptance range must be selected together.
When a QC result falls outside its accepted range, the laboratory should investigate the cause, such as problems with the medium, antimicrobial disks or solutions, inoculum, incubation, equipment, or reading procedure. Patient results affected by an unresolved QC failure should not be released until the problem has been assessed and corrected in accordance with the laboratory’s quality system.
Limitations of Antibiotic Susceptibility Testing
Although AST is essential for guiding antimicrobial treatment, laboratory tests cannot reproduce every condition found in the human body. Routine susceptibility methods generally assess bacterial growth under defined in vitro conditions. They do not fully represent immune responses, tissue structure, drug distribution, or all interactions within an infection site.
Routine AST usually examines free-living, or planktonic, bacteria rather than a mature biofilm, a surface-associated microbial community embedded in a surrounding matrix. Biofilm-associated growth can change antimicrobial responses, so an ordinary MIC is not a direct measurement of biofilm eradication. Tolerance describes reduced killing during antimicrobial exposure without necessarily increasing the MIC. In a laboratory study of Pseudomonas aeruginosa biofilms, Walters and colleagues found that oxygen limitation and low metabolic activity were associated with poor antibiotic killing. That finding concerns the tested biofilm model; it does not establish one mechanism for every biofilm infection.
Heteroresistance means that a bacterial population contains a less-susceptible subpopulation; sampling and test conditions can affect its detection. Band and colleagues described a small colistin-resistant subpopulation of Enterobacter cloacae that could escape routine diagnostic detection and contribute to treatment failure in mice. This demonstrates a possible limitation of testing, rather than the frequency of this problem in patients. Unexpected findings may need confirmatory testing and discussion between the laboratory and clinical team.
Small differences in MICs can reflect technical variability. A one-step change on a twofold dilution scale can move a result across a nearby breakpoint. Method comparisons therefore distinguish essential agreement, commonly MICs within one twofold dilution of the reference, from categorical agreement, matching interpretive categories. A test that falsely reports susceptibility to a resistant isolate is particularly concerning. Laboratories also apply the chosen system’s expected-phenotype and expert-rule guidance when a result is biologically unexpected.
Scientific Significance and Clinical Applications
AST is an important component of antimicrobial stewardship, which aims to improve patient outcomes while reducing avoidable antimicrobial use and its associated harms. When a patient has a suspected bacterial infection, clinicians may begin empirical treatment based on the likely pathogens, infection site, severity of illness, and local resistance patterns. Once culture, organism identification, and susceptibility results become available, the treatment plan can be reassessed.
If the clinical situation permits, the team may narrow or otherwise adjust antimicrobial therapy using the AST result together with the infection source, patient response, drug penetration, dosing requirements, and safety considerations. This process can reduce unnecessary broad-spectrum exposure while maintaining appropriate treatment. A susceptible laboratory result is an important part of the decision, but it does not replace clinical assessment.
Individual AST reports answer a question about one patient’s isolate. An antibiogram answers a different question: it summarizes susceptibility patterns across defined groups of isolates over time. Properly prepared local antibiograms can inform empirical treatment before an individual result is available; the individual report then supports reassessment. Consistent methods, appropriate inclusion rules, and a clear interpretation of S, I, SDD, and R are essential when building these summaries and contributing data to wider surveillance.
Conclusion
An AST report is useful when its measurements are reliable and its meaning is understood. A zone diameter, an MIC, and a resistance-gene result each provide different evidence. Good laboratory practice brings that evidence together through appropriate methods, quality control, and current interpretation rules; the clinical team then considers what it means for the patient and infection being treated.
For students, the central lesson is to follow the chain from observation to interpretation. Inhibition is not the same as killing, a detected gene is not a complete susceptibility profile, and EUCAST’s I is a susceptible category. Understanding those distinctions makes AST easier to learn and helps explain its place in responsible antibiotic use and resistance surveillance.
References
Balouiri, M., Sadiki, M., & Ibnsouda, S. K. (2016). Methods for in vitro evaluating antimicrobial activity: A review. Journal of Pharmaceutical Analysis, 6(2), 71–79. https://doi.org/10.1016/j.jpha.2015.11.005
Band, V. I., Crispell, E. K., Napier, B. A., Herrera, C. M., Tharp, G. K., Vavikolanu, K., Pohl, J., Read, T. D., Bosinger, S. E., Trent, M. S., Burd, E. M., & Weiss, D. S. (2016). Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nature Microbiology, 1(6), Article 16053. https://doi.org/10.1038/nmicrobiol.2016.53
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., Hamilton, C. W., Jenkins, T. C., Lipsett, P. A., Malani, P. N., May, L. S., Moran, G. J., Neuhauser, M. M., Newland, J. G., Ohl, C. A., . . . Trivedi, K. K. (2016). Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, 62(10), e51–e77. https://doi.org/10.1093/cid/ciw118
Clinical and Laboratory Standards Institute. (n.d.). Harmonized terminology database. Retrieved November 18, 2026, from https://htd.clsi.org/listallterms.asp
Clinical and Laboratory Standards Institute. (2015). Verification of commercial microbial identification and antimicrobial susceptibility testing systems (1st ed.; CLSI guideline M52). https://clsi.org/shop/standards/m52/
Clinical and Laboratory Standards Institute. (2022). Analysis and presentation of cumulative antimicrobial susceptibility test data (5th ed.; CLSI guideline M39). https://clsi.org/shop/standards/m39/
Clinical and Laboratory Standards Institute. (2026). Performance standards for antimicrobial susceptibility testing (36th ed.; CLSI standard M100). https://clsi.org/shop/standards/m100/
European Committee on Antimicrobial Susceptibility Testing. (n.d.). Definitions of S, I and R. Retrieved November 18, 2026, from https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/definition-of-s-i-and-r/
European Committee on Antimicrobial Susceptibility Testing. (2025). EUCAST disk diffusion method for antimicrobial susceptibility testing (Version 13.0). https://www.eucast.org/fileadmin/eucast/pdf/disk_test_documents/2025/Manual_v_13.0_EUCAST_Disk_Test_2025.pdf
European Committee on Antimicrobial Susceptibility Testing. (2026a). Breakpoint tables for interpretation of MICs and zone diameters (Version 16.1). https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/
European Committee on Antimicrobial Susceptibility Testing. (2026b). EUCAST RAST breakpoint table (Version 9.0). https://www.eucast.org/bacteria/rapid-ast-in-blood-culture/breakpoints-for-rapid-ast/
European Committee on Antimicrobial Susceptibility Testing. (2026c). EUCAST recommendations for MIC determination of aerobic and facultative anaerobic bacterial species with broth microdilution (Version 1.0, September 2026). https://www.eucast.org/fileadmin/eucast/pdf/Document_Archive/bacteria/disk_diffusion_methodology/EUCAST_recommendations_for_broth_microdilution_MIC_determination_September_2026.pdf
European Committee on Antimicrobial Susceptibility Testing. (2026d). Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST (Version 16.0). https://www.eucast.org/fileadmin/eucast/pdf/disk_test_documents/2026/v_16.0_EUCAST_QC_tables_routine_and_extended_QC.pdf
Hattab, S., Ma, A. H., Tariq, Z., Vega Prado, I., Drobish, I., Lee, R., & Yee, R. (2024). Rapid phenotypic and genotypic antimicrobial susceptibility testing approaches for use in the clinical laboratory. Antibiotics, 13(8), Article 786. https://doi.org/10.3390/antibiotics13080786
Jonasson, E., Matuschek, E., & Kahlmeter, G. (2020). The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles. Journal of Antimicrobial Chemotherapy, 75(4), 968–978. https://doi.org/10.1093/jac/dkz548
Matuschek, E., Brown, D. F. J., & Kahlmeter, G. (2014). Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clinical Microbiology and Infection, 20(4), O255–O266. https://doi.org/10.1111/1469-0691.12373
Walters, M. C., III, Roe, F., Bugnicourt, A., Franklin, M. J., & Stewart, P. S. (2003). Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrobial Agents and Chemotherapy, 47(1), 317–323. https://doi.org/10.1128/AAC.47.1.317-323.2003
World Health Organization. (2025a, October 13). Global antibiotic resistance surveillance report 2025: Summary. https://www.who.int/publications/i/item/B09585
World Health Organization. (2025b, October 13). WHO warns of widespread resistance to common antibiotics worldwide. https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide

No comments:
Post a Comment